385 related articles for article (PubMed ID: 9744770)
41. Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia.
Innocenti F; Danesi R; Favre C; Nardi M; Menconi MC; Di Paolo A; Bocci G; Fogli S; Barbara C; Barachini S; Casazza G; Macchia P; Del Tacca M
Ther Drug Monit; 2000 Aug; 22(4):375-82. PubMed ID: 10942174
[TBL] [Abstract][Full Text] [Related]
42. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
Tolar J; Bostrom BC; La MK; Sather HN
Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
[TBL] [Abstract][Full Text] [Related]
43. Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study.
Lowe ES; Kitchen BJ; Erdmann G; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Woods W; Franklin J; Widemann BC; Balis FM; Murphy RF; Adamson PC
Cancer Chemother Pharmacol; 2001 Mar; 47(3):199-205. PubMed ID: 11320662
[TBL] [Abstract][Full Text] [Related]
44. Role of TPMT and ITPA variants in mercaptopurine disposition.
Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose.
Welch J; Lennard L; Morton GC; Lilleyman JS
Ther Drug Monit; 1997 Aug; 19(4):382-5. PubMed ID: 9263376
[TBL] [Abstract][Full Text] [Related]
46. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
[TBL] [Abstract][Full Text] [Related]
47. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.
Lennard L; Lilleyman JS; Van Loon J; Weinshilboum RM
Lancet; 1990 Jul; 336(8709):225-9. PubMed ID: 1973780
[TBL] [Abstract][Full Text] [Related]
48. [Therapeutic drug monitoring of 6-thioguanine nucleotides in paediatric acute lymphoblastic leukaemia: interest and limits].
Fakhoury M; de Beaumais T; Médard Y; Jacqz-Aigrain E;
Therapie; 2010; 65(3):187-93. PubMed ID: 20699069
[TBL] [Abstract][Full Text] [Related]
49. Monitoring of thiopurine metabolites - a high-performance liquid chromatography method for clinical use.
Vikingsson S; Almer S; Peterson C; Carlsson B; Josefsson M
J Pharm Biomed Anal; 2013 Mar; 75():145-52. PubMed ID: 23261807
[TBL] [Abstract][Full Text] [Related]
50. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
Fakhoury M; Andreu-Gallien J; Mahr A; Medard Y; Azougagh S; Vilmer E; Jacqz-Aigrain E
J Clin Pharm Ther; 2007 Dec; 32(6):633-9. PubMed ID: 18021342
[TBL] [Abstract][Full Text] [Related]
51. Reversed-phase high-performance liquid chromatographic assay method for quantitating 6-mercaptopurine and its methylated and non-methylated metabolites in a single sample.
Mawatari H; Kato Y; Nishimura S; Sakura N; Ueda K
J Chromatogr B Biomed Sci Appl; 1998 Sep; 716(1-2):392-6. PubMed ID: 9824258
[TBL] [Abstract][Full Text] [Related]
52. Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia.
Keuzenkamp-Jansen CW; De Abreu RA; Blom HJ; Bökkerink JP; Trijbels JM
Biochem Pharmacol; 1996 May; 51(9):1165-71. PubMed ID: 8645339
[TBL] [Abstract][Full Text] [Related]
53. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
[TBL] [Abstract][Full Text] [Related]
54. Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy.
Cuffari C; Seidman EG; Latour S; Théorêt Y
Can J Physiol Pharmacol; 1996 May; 74(5):580-5. PubMed ID: 8884023
[TBL] [Abstract][Full Text] [Related]
55. Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in Crohn's disease.
de Boer NK; Derijks LJ; Keizer-Garritsen JJ; Lambooy LH; Ruitenbeek W; Hooymans PM; van Bodegraven AA; de Jong DJ
J Clin Pharmacol; 2007 Feb; 47(2):187-91. PubMed ID: 17244769
[TBL] [Abstract][Full Text] [Related]
56. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
Lennard L; Richards S; Cartwright CS; Mitchell C; Lilleyman JS; Vora A;
Clin Pharmacol Ther; 2006 Oct; 80(4):375-83. PubMed ID: 17015055
[TBL] [Abstract][Full Text] [Related]
57. Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens.
Innocenti F; Danesi R; Bocci G; Fogli S; Di Paolo A; Del Tacca M
Cancer Chemother Pharmacol; 1999; 43(2):133-40. PubMed ID: 9923818
[TBL] [Abstract][Full Text] [Related]
58. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
[TBL] [Abstract][Full Text] [Related]
59. Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization.
Lilleyman JS; Lennard L; Rees CA; Morgan G; Maddocks JL
Br J Cancer; 1984 Jun; 49(6):703-7. PubMed ID: 6587901
[TBL] [Abstract][Full Text] [Related]
60. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
